On March 23, 2017 Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, reported that data from its successful Phase 2a study of topsalysin, which evaluated the drug as a focal treatment for localized prostate cancer, will be presented as a poster on March 26, 2017 at the 32nd Annual European Association of Urology in London, UK (Press release, Sophiris Bio, MAR 23, 2017, View Source [SID1234518267]). The poster has been selected by conference organizers as one of the best posters at the congress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract No. 758: "Intra-prostatic injection of PRX302 to focally ablate clinically significant prostate cancer: An open label, phase 2a study"
Presenting Author: Dr. Yaalini Shanmugabavan, Division of Surgery and Interventional Sciences, University College London, London, UK
Poster Session: Poster Session 57 – Prostate cancer: Is the future focal?
Time: March 26, 2017 from 3:45 pm – 5:15 pm GMT

The abstract related to the poster can be accessed through the European Association of Urology Congress website at View Source